To ascertain the impact of p110α activating mutations in tumor initiation and progression, we combined myr-p110α with frequently co-occurring mutations of two genes, p53 and Kras, to generate novel models of breast, lung and potentially other cancers whose induction is controlled by the researcher. This evidence concerns the gene TP53 and neoplasm.